How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comSAXON-PC: A Phase II Randomized Trial of Stereotactic Body Radiation Therapy (SBRT) And Radium (Ra-223) Dichloride for Oligorecurrent, Non-castrate Resistant Prostate Cancer
Description:
Participants will either receive treatment with standard SBRT and the study drug Radium (Ra-223) dichloride, or standard SBRT alone.
Sponsor:
Memorial Sloan Kettering Cancer Center
Phase:
Phase 2
Government Study Link:
NCT05133440 - Click here to see study onClinicalTrials.gov
Isotope(s):
RADIUM-223
Radioisotope: Ra-223
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 11.4 Days
Decay Mode: ALPHA, BETA, GAMMA
Energy: Alpha (95%) 5-7.5 MeV Beta (3.6%) 445-492 keV Gamma (1%) 82-402 keV
Range: In Tissue <100 micrometers
Decay Daughters: 4 alpha daughters: Rn219, Po211,215, Bi211
Status: FDA Approval: XOFIGO® (2013)
Target(s):
Share your feedback
Help us improve your experience